Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

15.9K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab.

Kidney international reports·2026
Same author

Scoping Review of Global Kidney Genetics Clinic Models and Outcomes.

Kidney international reports·2026
Same author

Nur77 agonism invigorates Natural Killer cell immunity against hepatocellular carcinoma.

Nature communications·2026
Same author

HnRNP A1 and A2B1 enforce Ezh2 mRNA splicing to promote germinal center B cell responses.

Nature communications·2026
Same author

Engineering a TACI×CD3 Bispecific Antibody to Redirect T Cells Against Multiple Myeloma.

Blood advances·2026
Same author

Efficacy and Safety of Rituximab Therapy to Sustain Remission in Young Children With Childhood Nephrotic Syndrome.

Kidney international reports·2026

Related Experiment Video

Updated: Jan 13, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

B-cell activation underpins Rituximab response in focal segmental glomerulosclerosis.

Liangjian Lu1, Chang Yien Chan2, Mya Than2

  • 1Khoo Teck Puat-National University Children's Medical Institute, National University Health System 119260, Singapore.

Translational Research : the Journal of Laboratory and Clinical Medicine
|January 8, 2026
PubMed
Summary

Childhood focal segmental glomerulosclerosis (FSGS) patients with T-cell hypo-responsiveness show B-cell activation and respond to Rituximab. Resting B-cell cytokine production predicts Rituximab response and its duration in FSGS.

Keywords:
B-cellsCytokinesIdiopathic nephrotic syndromeRituximab

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K
A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

8.1K

Related Experiment Videos

Last Updated: Jan 13, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K
A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

8.1K

Area of Science:

  • Nephrology
  • Immunology
  • Pediatric Nephrology

Background:

  • Primary focal segmental glomerulosclerosis (FSGS) pathogenesis is poorly understood, with limited treatment options.
  • Rituximab shows efficacy in some FSGS patients, particularly those with T-cell hypo-responsiveness, but mechanisms are unclear.
  • Understanding the interplay between B-cell activation and T-cell function is crucial for optimizing FSGS treatment.

Purpose of the Study:

  • To investigate the association between B-cell activation and T-cell hypo-responsiveness in childhood-onset FSGS.
  • To explore the role of these immune markers in predicting Rituximab response and its duration.
  • To elucidate the mechanism by which B-cells may contribute to podocyte damage in FSGS.

Main Methods:

  • Recruited 33 patients with childhood-onset FSGS treated with Rituximab.
  • Defined T-cell hypo-responsiveness by stimulated T-cell IFNγ levels (<2.5%).
  • Assessed B-cell activation via CD80 expression and cytokine production; evaluated podocyte damage using cultured podocytes and patient B-cell supernatants.

Main Results:

  • T-cell hypo-responsiveness was significantly associated with Rituximab response (OR: 5.4, p=0.028).
  • Patients with T-cell hypo-responsiveness exhibited elevated activated B-cells (CD19+CD80+) and increased resting B-cell cytokine production.
  • Resting B-cell supernatants from hypo-responsive patients induced cytoskeletal rearrangements in podocytes.
  • Resting B-cell cytokine production, along with T-cell responsiveness, strongly predicted Rituximab response (AUC 0.922) and duration (AUC 0.958).

Conclusions:

  • Rituximab response in childhood FSGS is linked to a subgroup with B-cell mediated disease characterized by B-cell activation.
  • Elevated resting B-cell cytokine production contributes to podocyte damage and can predict Rituximab treatment efficacy and longevity.
  • Targeting B-cell activation may be a promising therapeutic strategy for FSGS patients with T-cell hypo-responsiveness.